|
|
|
|
LEADER |
03049nam a2200505 4500 |
001 |
978-981-10-8806-3 |
003 |
DE-He213 |
005 |
20191027152432.0 |
007 |
cr nn 008mamaa |
008 |
180502s2018 si | s |||| 0|eng d |
020 |
|
|
|a 9789811088063
|9 978-981-10-8806-3
|
024 |
7 |
|
|a 10.1007/978-981-10-8806-3
|2 doi
|
040 |
|
|
|d GrThAP
|
050 |
|
4 |
|a RS400-431
|
072 |
|
7 |
|a PSB
|2 bicssc
|
072 |
|
7 |
|a SCI013020
|2 bisacsh
|
072 |
|
7 |
|a PSB
|2 thema
|
082 |
0 |
4 |
|a 615.19
|2 23
|
100 |
1 |
|
|a Giltrap, Andrew.
|e author.
|4 aut
|4 http://id.loc.gov/vocabulary/relators/aut
|
245 |
1 |
0 |
|a Total Synthesis of Natural Products with Antimicrobial Activity
|h [electronic resource] /
|c by Andrew Giltrap.
|
250 |
|
|
|a 1st ed. 2018.
|
264 |
|
1 |
|a Singapore :
|b Springer Singapore :
|b Imprint: Springer,
|c 2018.
|
300 |
|
|
|a XXIV, 268 p. 144 illus., 59 illus. in color.
|b online resource.
|
336 |
|
|
|a text
|b txt
|2 rdacontent
|
337 |
|
|
|a computer
|b c
|2 rdamedia
|
338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
347 |
|
|
|a text file
|b PDF
|2 rda
|
490 |
1 |
|
|a Springer Theses, Recognizing Outstanding Ph.D. Research,
|x 2190-5053
|
505 |
0 |
|
|a Introduction -- Total Synthesis of Teixobactin -- Synthesis of Deshydroxy Skyllamycins A-C -- Total Synthesis of Skyllamycins A-C -- Experimental.
|
520 |
|
|
|a This thesis focuses on the development of efficient and scalable total syntheses of natural products that can be used as preferred scaffolds for anti-infective drug discovery. It describes the total synthesis of two classes of antimicrobial non-ribosomal peptides (NRPs) - teixobactin and the skyllamycins - with subsequent biological evaluation. The first part describes the first total synthesis of teixobactin by means of a solid-phase peptide synthesis-macrolactamisation approach, yielding a synthetic natural product that can combat a number of clinically relevant Gram-positive bacterial pathogens. The second part describes the first total synthesis of skyllamycins A-C, a family of structurally complex cyclic NRPs, which inhibit the growth of the Pseudomonas aeruginosa biofilms that are responsible for significant mortality among cystic fibrosis patients.
|
650 |
|
0 |
|a Medicinal chemistry.
|
650 |
|
0 |
|a Medical biochemistry.
|
650 |
|
0 |
|a Drug resistance.
|
650 |
1 |
4 |
|a Medicinal Chemistry.
|0 http://scigraph.springernature.com/things/product-market-codes/C28000
|
650 |
2 |
4 |
|a Medical Biochemistry.
|0 http://scigraph.springernature.com/things/product-market-codes/H35005
|
650 |
2 |
4 |
|a Drug Resistance.
|0 http://scigraph.springernature.com/things/product-market-codes/B16020
|
710 |
2 |
|
|a SpringerLink (Online service)
|
773 |
0 |
|
|t Springer eBooks
|
776 |
0 |
8 |
|i Printed edition:
|z 9789811088056
|
776 |
0 |
8 |
|i Printed edition:
|z 9789811088070
|
776 |
0 |
8 |
|i Printed edition:
|z 9789811342455
|
830 |
|
0 |
|a Springer Theses, Recognizing Outstanding Ph.D. Research,
|x 2190-5053
|
856 |
4 |
0 |
|u https://doi.org/10.1007/978-981-10-8806-3
|z Full Text via HEAL-Link
|
912 |
|
|
|a ZDB-2-CMS
|
950 |
|
|
|a Chemistry and Materials Science (Springer-11644)
|